靶向烟曲霉的CAR T细胞在临床前模型中可有效治疗侵袭性肺曲霉病
研究构建了靶向烟曲霉(Aspergillus fumigatus)的嵌合抗原受体(Af-CAR)T细胞,其识别烟曲霉菌丝细胞壁保守蛋白抗原。体外实验中Af-CAR T细胞对烟曲霉菌株及临床分离株发挥直接抗真菌作用;在免疫缺陷小鼠侵袭性肺曲霉病(IPA)模型中,CD8+ Af-CAR T细胞定位于感染部位、激活固有免疫细胞并减少肺部真菌负荷,过继转移CD8+ Af-CAR T细胞较CD4+ Af-CAR T细胞抗真菌效力更强并改善总生存期。
要点
- Af-CAR T细胞可识别烟曲霉菌丝细胞壁保守蛋白抗原并直接损伤菌丝。
- CD8+ Af-CAR T细胞释放穿孔素和颗粒酶B,并分泌细胞因子激活巨噬细胞。
- 免疫缺陷小鼠IPA模型中,CD8+ Af-CAR T细胞减少肺部真菌负荷并改善总生存期。
核心结论
- 基因工程T细胞具有治疗常规抗菌治疗难以控制的侵袭性感染性疾病的潜力,并支持Af-CAR T细胞疗法治疗IPA的临床开发。
研究设计与样本
- 研究为临床前研究,在体外和体内模型中评价基因工程烟曲霉特异性CAR T细胞(Af-CAR T细胞)的抗真菌反应。
- 体内采用免疫缺陷小鼠IPA模型进行过继转移实验。
主要发现
- 表达Af-CAR的T细胞识别烟曲霉菌株和临床分离株,并对烟曲霉菌丝发挥直接抗真菌作用。
- CD8+ Af-CAR T细胞释放穿孔素和颗粒酶B并损伤烟曲霉菌丝。
- CD8+和CD4+ Af-CAR T细胞产生细胞因子,激活巨噬细胞以增强抗真菌作用。
- 免疫缺陷小鼠IPA模型中,CD8+ Af-CAR T细胞定位于感染部位、与固有免疫细胞相互作用并减少肺部真菌负荷。
- 过继转移CD8+ Af-CAR T细胞较CD4+ Af-CAR T细胞抗真菌效力更强,并改善总生存期。
临床怎么用
- 原文结论支持Af-CAR T细胞疗法治疗IPA的临床开发,未给出具体临床应用推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aspergillus fumigatus is a ubiquitous mold that can cause severe infections in immunocompromised patients, typically manifesting as invasive pulmonary aspergillosis (IPA). Adaptive and innate immune cells that respond to A. fumigatus are present in the endogenous repertoire of patients with IPA but are infrequent and cannot be consistently isolated and expanded for adoptive immunotherapy. Therefore, we gene-engineered A. fumigatus-specific chimeric antigen receptor (Af-CAR) T cells and demonstrate their ability to confer antifungal reactivity in preclinical models in vitro and in vivo. We generated a CAR targeting domain AB90-E8 that recognizes a conserved protein antigen in the cell wall of A. fumigatus hyphae. T cells expressing the Af-CAR recognized A. fumigatus strains and clinical isolates and exerted a direct antifungal effect against A. fumigatus hyphae. In particular, CD8+ Af-CAR T cells released perforin and granzyme B and damaged A. fumigatus hyphae. CD8+ and CD4+ Af-CAR T cells produced cytokines that activated macrophages to potentiate the antifungal effect. In an in vivo model of IPA in immunodeficient mice, CD8+ Af-CAR T cells localized to the site of infection, engaged innate immune cells, and reduced fungal burden in the lung. Adoptive transfer of CD8+ Af-CAR T cells conferred greater antifungal efficacy compared to CD4+ Af-CAR T cells and an improvement in overall survival. Together, our study illustrates the potential of gene-engineered T cells to treat aggressive infectious diseases that are difficult to control with conventional antimicrobial therapy and support the clinical development of Af-CAR T cell therapy to treat IPA.
引用
- Seif M, Kakoschke TK, Ebel F, et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med. 2022. PMID: 36170447. doi:10.1126/scitranslmed.abh1209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。